Showing results (101-110 of 292) with videos related to

Sort By:
Pageof 30
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 16, 2020
European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical PracticeLiese Barbier, Steven Simoens, Arnold G Vulto, et al.
Acta Ophthalmologica|April 30, 2026
Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time-series analysisElif Car, Isabelle Huys, Steven Simoens, et al.
Orphanet Journal of Rare Diseases|September 28, 2012
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Wills Hughes-Wilson, Ana Palma, Ad Schuurman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 4, 2019
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!Binita Dutta, Isabelle Huys, Arnold G Vulto, et al.
Frontiers in Pharmacology|September 8, 2017
Time Investment in Drug Supply Problems by Flemish Community PharmaciesElfi De Weerdt, Steven Simoens, Minne Casteels, et al.
Frontiers in Pharmacology|February 7, 2022
Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European CountriesAlessandra Blonda, Teresa Barcina Lacosta, Mondher Toumi, et al.
Pharmacoeconomics|August 16, 2005
Pharmaceutical policy regarding generic drugs in BelgiumSteven Simoens, Kristien De Bruyn, Marc Bogaert, et al.
Clinical Drug Investigation|August 12, 2024
Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell DiseaseKhadidja Abdallah, Isabelle Huys, Kathleen J Claes, et al.
The Patient|August 29, 2020
Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA RepresentativesEline van Overbeeke, Valérie Forrester, Steven Simoens, et al.
Frontiers in Pharmacology|March 30, 2026
Addressing clinical uncertainties in ATMP reimbursement: a review of methodological guidelines and European practiceLotte Delemarre, Isabelle Huys, Walter Van Dyck, et al.
Pageof 30